Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases

Epidermal growth factor receptor tyrosine kinase inhibitors, gefitnib and erlotinib, are effective for advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutation. However, interstitial lung disease induced by these drugs is sometimes fatal, and discontinuation of the medi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Arakawa, Nobuhito, Tsujita, Akihiro, Saito, Noriko, Ishikawa, Shigemi, Ohno, Shoji
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2013
Assuntos:
Case Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184641/
https://ncbi.nlm.nih.gov/pubmed/25473530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.12
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares